March 9th, 2000: PharmaSwiss d.o.o Slovenia established and started its operations in Ljubljana.
April 2000: BMS and PharmaSwiss signed a 5 year renewable contract. PharmaSwiss commenced trading. All existing BMS employees in ex-Yugoslavia were invited to join PharmaSwiss.
May 23rd , 2000: PharmaSwiss SA Representative Office opened in Belgrade (Serbia).
November, 2000: PharmaSwiss launched Consumer Medicines in Croatia and achieved Taxol funding breakthrough in Croatia & Slovenia.
February, 2001: PharmaSwiss received warehouse license from Slovenia for both bonded and non-bonded Distribution Center. PharmaSwiss d.o.o established in Belgrade (Serbia).
April, 2001: PharmaSwiss launched Monopril (a novel ACE inhibitor by BMS) in Serbia, followed by Croatia and Slovenia in the following year.
June, 2001: PharmaSwiss d.o.o Croatia established in Zagreb.
July, 2001: PharmaSwiss Bosnia & Herzegovina d.o.o established in Sarajevo with representative office in Banja Luka (Republic of Srpska).
February, 2002: Taxol ovarian funding campaign in Croatia and Slovenia – resulting in creation of exclusive Taxol fund with dedicated funding for ovarian cancer patients. Upsarin became market leader amongst acetylsalicylic products in Kosovo and keeps No 1 position in a very crowded market up to today.
2002: Ipsen, Fujisawa and Ferring signed a 5 year renewable contract with PharmaSwiss. Taxol (paclitaxel by BMS indicated in breast and ovarian cancers) launched in Macedonia: 2002-2005 becoming best-selling oncology product in Macedonia. Efferalgan overtakes market leader position of paracetamols market at Kosovo and marketing it till 2009.
June, 2002: Launch of Megace OS in Cachexia in Slovenia and Croatia.
August, 2002: Launch of Diclofenac Duo (by Klinge) in Serbia & Montenegro. Fully-fledged selling and marketing operation in Skopje, Macedonia
October, 2003: UK leading name in health & beauty - Boots signed a contract with PharmaSwiss, including exclusive representation in Slovenia, Serbia and Macedonia. Strepsils core line products were launched in Serbia and Slovenia.
November, 2003: Taxol recieved full reimbursement status in Serbia – reached 79% market share of total taxane market in Serbia by 2004.